These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24323134)

  • 41. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 42. International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?
    Calice-Silva V; Muenz D; Wong MMY; McCullough K; Charytan D; Reichel H; Robinson B; Stengel B; Massy ZA; Pecoits-Filho R;
    Lipids Health Dis; 2023 May; 22(1):67. PubMed ID: 37231413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
    Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
    Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
    Kasiske B; Cosio FG; Beto J; Bolton K; Chavers BM; Grimm R; Levin A; Masri B; Parekh R; Wanner C; Wheeler DC; Wilson PW;
    Am J Transplant; 2004; 4 Suppl 7():13-53. PubMed ID: 15027968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of statins on renal function.
    Agarwal R
    Mayo Clin Proc; 2007 Nov; 82(11):1381-90. PubMed ID: 17976359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical significance of treatment for dyslipidemia in CKD].
    Ikemori A; Kimura K
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1287-94. PubMed ID: 24288965
    [No Abstract]   [Full Text] [Related]  

  • 49. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.
    Jadoul M; Berenguer MC; Doss W; Fabrizi F; Izopet J; Jha V; Kamar N; Kasiske BL; Lai CL; Morales JM; Patel PR; Pol S; Silva MO; Balk EM; Gordon CE; Earley A; Di M; Martin P
    Kidney Int; 2018 Oct; 94(4):663-673. PubMed ID: 30243313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.
    Cheung AK; Chang TI; Cushman WC; Furth SL; Hou FF; Ix JH; Knoll GA; Muntner P; Pecoits-Filho R; Sarnak MJ; Tobe SW; Tomson CRV; Lytvyn L; Craig JC; Tunnicliffe DJ; Howell M; Tonelli M; Cheung M; Earley A; Mann JFE
    Kidney Int; 2021 Mar; 99(3):559-569. PubMed ID: 33637203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A; Greer E; Delos Santos R; Rueda J
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
    Kliger AS; Foley RN; Goldfarb DS; Goldstein SL; Johansen K; Singh A; Szczech L
    Am J Kidney Dis; 2013 Nov; 62(5):849-59. PubMed ID: 23891356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multidisciplinary team care for CKD-MBD. Achieving KDIGO guideline recommendations in the bundling era.
    McCann L; Hoefs M
    Nephrol News Issues; 2014 Apr; 28(4):24-6, 28, 30-2 passim. PubMed ID: 24960985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statins in patients with chronic kidney disease: new evidence.
    Savino M; Garofalo C; De Paris V; Michini C; Pirro L; Palmisano R; Provenzano M; Minutolo R; Conte G; De Nicola L
    Minerva Urol Nefrol; 2013 Sep; 65(3):217-23. PubMed ID: 23872633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology.
    Pontremoli R; Bellizzi V; Bianchi S; Bigazzi R; Cernaro V; Del Vecchio L; De Nicola L; Leoncini G; Mallamaci F; Zoccali C; Buemi M
    J Nephrol; 2020 Jun; 33(3):417-430. PubMed ID: 32065354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonculprit coronary plaque characteristics of chronic kidney disease.
    Kato K; Yonetsu T; Jia H; Abtahian F; Vergallo R; Hu S; Tian J; Kim SJ; Lee H; McNulty I; Lee S; Uemura S; Jang Y; Park SJ; Mizuno K; Yu B; Jang IK
    Circ Cardiovasc Imaging; 2013 May; 6(3):448-56. PubMed ID: 23536265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statin treatment and adherence to national cholesterol guidelines after ischemic stroke.
    Ovbiagele B; Saver JL; Bang H; Chambless LE; Nassief A; Minuk J; Toole JF; Crouse JR;
    Neurology; 2006 Apr; 66(8):1164-70. PubMed ID: 16636231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.